Pulmuone was designated as an unfaithful disclosure corporation in March 2025 due to delayed disclosure of a subsidiary merger decision, but has since strengthened prevention systems through internal training and manual reorganization.
The board consists of 11 members including 8 outside directors (73%), ensuring independence, and includes 3 female directors (27.3%) for diversity.
The audit committee is composed entirely of 4 outside directors, guaranteeing independence, with 2 accounting/financial experts enhancing expertise.
The 42nd regular general shareholders' meeting was held on March 31, 2026, with all agendas approved by over 94.9% approval rate.
Cash dividend is 102 won per common share, same as previous year, maintaining a stable dividend policy (dividend yield 0.8%).
In September 2025, the company disclosed a 'Value-up Plan' and has continued board-level discussions and investor conference calls for communication.
[AI Comprehensive Analysis]The corporate governance report demonstrates strong governance practices and shareholder communication efforts, but the past unfaithful disclosure record may negatively impact investor confidence. Short-term stock price impact is limited, and long-term investment risk is relatively low.